Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Atlanta, GA
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Prairie Village, KA
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Weymouth, MA
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Weymouth, MA
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Brooklyn, NY
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Jamaica, NY
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Jamaica, NY
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Staten Island, NY
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Portland, OR
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Houston, TX
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
San Antonio, TX
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Seattle, WA
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Garden Grove, CA
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Austin, TX
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Study Using Pregnenolone to Treat Bipolar Depression
A Randomized, Double Blind, Placebo-controlled Trial of Pregnenolone for Bipolar Depression
Status: Enrolling
Updated:  3/1/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Study Using Pregnenolone to Treat Bipolar Depression
A Randomized, Double Blind, Placebo-controlled Trial of Pregnenolone for Bipolar Depression
Status: Enrolling
Updated: 3/1/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Kappa Opioid Receptor Imaging in Depression (KOR Depression)
Kappa Opioid Receptor Imaging in Depression (KOR Depression)
Status: Enrolling
Updated:  3/2/2016
NYU School of Medicine
mi
from
New York, NY
Kappa Opioid Receptor Imaging in Depression (KOR Depression)
Kappa Opioid Receptor Imaging in Depression (KOR Depression)
Status: Enrolling
Updated: 3/2/2016
NYU School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation
Status: Enrolling
Updated:  3/7/2016
VA Pittsburgh Healthcare System (University Drive)
mi
from
Pittsburgh, PA
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation
Status: Enrolling
Updated: 3/7/2016
VA Pittsburgh Healthcare System (University Drive)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Woodland International Research Group, Inc.
mi
from
Little Rock, AR
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Woodland International Research Group, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
K & S Professional Research Services
mi
from
Little Rock, AR
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
K & S Professional Research Services
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
South Coast Clinical Trials Inc.
mi
from
Anaheim, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
South Coast Clinical Trials Inc.
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Diligent Clinical Trials
mi
from
Downey, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Diligent Clinical Trials
mi
from
Downey, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Synergy Clinical Research Center
mi
from
Escondido, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Synergy Clinical Research Center
mi
from
Escondido, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Pacific Research Partners, LLC
mi
from
Oakland, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Pacific Research Partners, LLC
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
North County Clinical Research
mi
from
Oceanside, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
North County Clinical Research
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
BreakThrough Clinical Trials, LLC
mi
from
San Bernardino, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
BreakThrough Clinical Trials, LLC
mi
from
San Bernardino, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Cnri, Llc
mi
from
San Diego, CA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Cnri, Llc
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Professional Clinical Research, Inc.
mi
from
Aventura, FL
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Professional Clinical Research, Inc.
mi
from
Aventura, FL
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
University of Florida
mi
from
Gainesville, FL
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Segal Institute for Clinical Research
mi
from
Hollywood, FL
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Segal Institute for Clinical Research
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Accurate Clinical Trials
mi
from
Kissimmee, FL
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Accurate Clinical Trials
mi
from
Kissimmee, FL
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
AMB Research Center
mi
from
Miami, FL
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
AMB Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Lakeside Behavioral Health
mi
from
Orlando, FL
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Lakeside Behavioral Health
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
University of South Florida Dept of Psychiatry and Neurosciences
mi
from
Tampa, FL
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
University of South Florida Dept of Psychiatry and Neurosciences
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Alexian Brothers Center for Psychiatric Research
mi
from
Hoffman Estates, IL
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Alexian Brothers Center for Psychiatric Research
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Precise Research Centers
mi
from
Flowood, MS
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Precise Research Centers
mi
from
Flowood, MS
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Millennium Psychiatric Associate
mi
from
Creve Coeur, MO
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Millennium Psychiatric Associate
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
PsychCare Consultants Research
mi
from
St. Louis, MO
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
PsychCare Consultants Research
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
CRI Lifetree
mi
from
Marlton, NJ
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
CRI Lifetree
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Inquest Clinical Group/ Global Research Associates
mi
from
Hope Mills, NC
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Inquest Clinical Group/ Global Research Associates
mi
from
Hope Mills, NC
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Midwest Clinical Research Center
mi
from
Dayton, OH
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Midwest Clinical Research Center
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Oklahoma Clinical Research Center
mi
from
Oklahoma City, OK
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Oklahoma Clinical Research Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Lehigh Center for Clinical Research
mi
from
Allentown, PA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Belmont Center for Comprehensive Treatment
mi
from
Philadelphia, PA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Belmont Center for Comprehensive Treatment
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
University of Pittsburgh Medical Center (UPMC)
mi
from
Pittsburgh, PA
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
University of Pittsburgh Medical Center (UPMC)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated:  3/8/2016
Carolina Clinical Trials, Inc.
mi
from
Charleston, SC
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Status: Enrolling
Updated: 3/8/2016
Carolina Clinical Trials, Inc.
mi
from
Charleston, SC
Click here to add this to my saved trials